Adverse events (all adverse events) at 24 weeks · vascular dementia and other vascular cognitive impairments
Donepezil 10 mg leads to higher adverse events (all adverse events) at 24 weeks compared with placebo (high certainty).
1 finding from 1 review
Intervention not reported
MSP compared with IHC · people with glioblastoma undergoing treatment with temozolomide Outcome being predicted: overall survival (time to death)
1 finding from 1 review
Intervention not reported
Other techniques (against MSP or PSQ) · people with glioblastoma undergoing treatment with temozolomide Outcome being predicted: overall survival (time to death)
1 finding from 1 review
Intervention not reported
PSQ compared with IHC · people with glioblastoma undergoing treatment with temozolomide Outcome being predicted: overall survival (time to death)
1 finding from 1 review
Intervention not reported
PSQ compared with MSP · people with glioblastoma undergoing treatment with temozolomide Outcome being predicted: overall survival (time to death)
1 finding from 1 review
Intervention not reported
Variants of PSQ · people with glioblastoma undergoing treatment with temozolomide Outcome being predicted: overall survival (time to death)
1 finding from 1 review
Intervention not reported
qMSP (against MSP or PSQ) · people with glioblastoma undergoing treatment with temozolomide Outcome being predicted: overall survival (time to death)
1 finding from 1 review
Intervention not reported
Bead array (against MSP or PSQ) · people with glioblastoma undergoing treatment with temozolomide Outcome being predicted: overall survival (time to death)
1 finding from 1 review
Intervention not reported
PCR‐mRNA (against MSP or PSQ) · people with glioblastoma undergoing treatment with temozolomide Outcome being predicted: overall survival (time to death)
1 finding from 1 review
Intervention not reported
MS‐MLPA (against MSP or PSQ) · people with glioblastoma undergoing treatment with temozolomide Outcome being predicted: overall survival (time to death)
1 finding from 1 review
Intervention not reported
PCR‐HRM (against MSP or PSQ) · people with glioblastoma undergoing treatment with temozolomide Outcome being predicted: overall survival (time to death)
1 finding from 1 review
Overall survival · women with recurrent or FIGO stage IVB cervical cancer
Apatinib plus chemotherapy or chemotherapy/brachytherapy showed no clear difference in overall survival compared with chemotherapy or chemotherapy/brachytherapy (low certainty).
1 finding from 1 review
Specific adverse events: gastrointestinal perforations or fistulae ‐ not reported · women with recurrent or FIGO stage IVB cervical cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Specific adverse events: haemorrhage · women with recurrent or FIGO stage IVB cervical cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Specific adverse events: thromboembolic events ‐ not reported · women with recurrent or FIGO stage IVB cervical cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events: hypertension · women with recurrent or FIGO stage IVB cervical cancer
Apatinib plus chemotherapy or chemotherapy/brachytherapy may leads to higher specific adverse events: hypertension compared with chemotherapy or chemotherapy/brachytherapy (low certainty).
1 finding from 1 review
Serious adverse events ‐ not reported · women with recurrent or FIGO stage IVB cervical cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Economic evaluation ‐ not measured · women with recurrent or FIGO stage IVB cervical cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Outcome domain · COPD and at least one other long‐term condition
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life ‐ CAT · COPD and at least one other long‐term condition
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found